Lisa Gill

“Jim, I just want to go back to your comments around PAMA and just really understand two things. One, when we think about the Results Act, have you quantified what the impact of results would be.”

“I want to switch over to Carillon for a minute. When I look at the quarter, Carillon RX came in better than what our expectations were. You highlighted that part of this is due to product revenue.”

“I just want to talk about PAMA for a minute. So it's embedded within your guidance, but can you give a little more color around a couple of things? One, what the anticipation is around participation by the hospitals.”

“Can we spend a minute just talking about the regulatory environment? And really two things I just want to better understand here. The first would be potential regulatory changes.”

“I just was wondering if we could talk a bit about revenue per visit and the key drivers there. you talk about the specialty business. I'm just curious, you know, what the key drivers are.”